Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Tiziana Life Sciences Plc ADR (NQ: TLSA)
2.510   -0.210 (-7.72%)
Streaming Delayed Price  /  Updated: 2:11 PM EST, Jan 28, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 7,195
Open 2.610
Bid (Size) 2.510 (1)
Ask (Size) 2.700 (2)
Prev. Close 2.720
Today's Range 2.510 - 2.710
52wk Range 2.360 - 10.41
Shares Outstanding N/A
Dividend Yield N/A
Performance
YTD
-11.43%
-11.43%
1 Month
+6.36%
+6.36%
3 Month
-58.85%
-58.85%
6 Month
-64.90%
-64.90%
1 Year
-64.14%
-64.14%
Top News
More News
Tiziana Life Sciences Announces Appointment of Mr. Gregor MacRae to strengthen the Board
Tiziana Life Sciences plc ("Tiziana" or the "Company") (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and... Read More
from Business Wire News Releases
Tiziana Reports Phase 1 Clinical Data Demonstrating Oral Treatment with Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, is Well-tolerated in Healthy Volunteers
Tiziana Life Sciences plc (Nasdaq:TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory diseases and cancers, is pleased to report completion... Read More
from Business Wire News Releases
More News
Read More
Tiziana Life Sciences Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers
from Business Wire News Releases
Tiziana Life Sciences to Present at the 9th Annual LD Micro Invitational
from ACCESSWIRE
Tiziana Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers of Immunomodulation and Anti-inflammation in Healthy Vol
from Business Wire News Releases
Tiziana Life Sciences Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity with Milciclib Monotherapy in Advanced Sorafenib-refractory or -intolerant Patients with Unresectabl
from Business Wire News Releases
Tiziana Reports Phase 2a Clinical Data with Milciclib Monotherapy in Sorafenib-refractory or -intolerant patients with unresectable or metastatic Hepatocellular Carcinoma
from Business Wire News Releases
Tiziana Life Science reports Independent Third Party Article in New England Journal of Medicine on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays in progression of Type 1 Diabetes
from Business Wire News Releases
Newly Published Article Reporting Clinical Activity of Orally Administered OKT3, a Mouse Anti-CD3 Monoclonal Antibody, in Moderate to Severe Ulcerative Colitis Patients, Supports Tiziana’s Oral Monocl
from Business Wire News Releases
Mid-Day Market Update: Dow Surges Over 200 Points; Genetic Technologies Shares Spike Higher
category Eurozone , Intraday Update , BBBY , and 16 more.
from Benzinga
Tiziana Reports Encouraging Interim Clinical Data from an Ongoing Phase 2a Clinical Trial with Milciclib in Patients With Advanced Liver Cancer
from Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.